Zobrazeno 1 - 10
of 160
pro vyhledávání: ''
Autor:
Masaoki Ito, Andrés F. Cardona, Andrés Aguilar, Jordi Codony-Servat, Mariacarmela Santarpia, Rafael Rosell, Carlos González Pedraz, Oscar Arrieta
Publikováno v:
British Journal of Cancer
Epidermal growth factor receptor (EGFR) mutations in lung adenocarcinoma are a frequent class of driver mutations. Single EGFR tyrosine kinase inhibitor (TKI) provides substantial clinical benefit, but almost nil radiographic complete responses. Pati
Autor:
Irina Ostrovnaya, David B. Solit, Timothy R. Donahue, Eugene K. Cha, Ashley Marie Regazzi, Samuel Funt, Eugene J. Pietzak, Hikmat Al-Ahmadie, Gopakumar Iyer, Min Yuen Teo, Guido Dalbagni, Jonathan E. Rosenberg, Satish K. Tickoo, Victor E. Reuter, Kenneth Seier, Christopher Michael Tully, Bernard H. Bochner, Sherri M. Donat, Harry W. Herr, Dean F. Bajorin
Publikováno v:
British Journal of Cancer
Background Plasmacytoid urothelial carcinoma (PUC) is a rare, aggressive histologic variant of urothelial cancer characterised by a diffuse growth pattern and CDH1 mutation. We studied the efficacy of preoperative platinum-based chemotherapy in nonme
Autor:
Ying Jing, Yi Zhang, Minhua Yu, Mei-Chun Cai, Lin Cheng, Wenjing Wang, Xia Yin, Huaiwu Lu, Lihua Qiu, Caiyan Zhang, Haijiao Lu, Wen Di, Li Tan, Jie Wu, Jiejun Cheng, Guanglei Zhuang, Weihua Lou
Publikováno v:
British Journal of Cancer
Background We aimed to comprehensively evaluate the immunologic landscape at baseline and upon chemotherapy in cervical cancer. The information should aid ongoing clinical investigations of checkpoint blockade immunotherapies in this disease setting.
Autor:
Ming Chen, Bing Xia, Xilong Lian, Qing Liu, Zhao Jing, Bangxian Tan, Lingyu Ding, Ruifei Xie, Conghua Xie, Duojie Li, Wei Jiang, Anping Zheng, Congying Xie, Xiuhua Bian, Li Ma, Hongyan Zhang, Lvhua Wang, Dexi Du, Shixiu Wu, Wei Hu, Honglei Luo
Publikováno v:
British Journal of Cancer. 123:1616-1624
BackgroundTo report the long-term outcomes of a phase III trial designed to test two hypotheses: (1) elective nodal irradiation (ENI) is superior to conventional field irradiation (CFI), and (2) chemoradiotherapy plus erlotinib is superior to chemora
Autor:
Anna Larissa N. Niemeijer, Sara Sahba, Adrianus J. de Langen, Egbert F. Smit, Birgit I. Lissenberg-Witte, Erik Thunnissen
Publikováno v:
British Journal of Cancer, 123(3), 392-402. SPRINGERNATURE
Niemeijer, A L N, Sahba, S, Smit, E F, Lissenberg-Witte, B I, de Langen, A J & Thunnissen, E 2020, ' Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy ', British Journal of Cancer, vol. 123, no. 3, pp. 392-402 . https://doi.org/10.1038/s41416-020-0888-5
British Journal of Cancer, 123(3), 392-402. Nature Publishing Group
British Journal of Cancer
Niemeijer, A L N, Sahba, S, Smit, E F, Lissenberg-Witte, B I, de Langen, A J & Thunnissen, E 2020, ' Association of tumour and stroma PD-1, PD-L1, CD3, CD4 and CD8 expression with DCB and OS to nivolumab treatment in NSCLC patients pre-treated with chemotherapy ', British Journal of Cancer, vol. 123, no. 3, pp. 392-402 . https://doi.org/10.1038/s41416-020-0888-5
British Journal of Cancer, 123(3), 392-402. Nature Publishing Group
British Journal of Cancer
Background Immune checkpoint inhibitors are most beneficial in patients with high tumour PD-L1 expression. However, the use of PD-L1 expression is not straightforward. We investigated PD-L1 expression and immune cell (IC) infiltrates in non-small-cel
Autor:
Josep Tabernero, Tamas Hickish, Edouard Auclin, Jean-Luc Van Laethem, Julien Taieb, Dewi Vernerey, Aimery de Gramont, Thierry André, Maria Banzi
Publikováno v:
British Journal of Cancer
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Background: Adjuvant treatment for stage II colon cancer (CC) can be proposed to patients with high-risk disease. Recently, 2.35 ng/mL carcinoembryonic antigen (CEA) was identified as the best cut-off value. This post hoc analysis of the MOSAIC trial
Autor:
Maurice B Loughrey, Amelie Viratham-Pulsawatdi, Mark Lawler, Matthew P. Humphries, James Robineau, Matthew Alderdice, Susan D. Richman, Enric Domingo, Louise Brown, Phil Quirke, Peter Bankhead, Kris McCombe, Victoria Bingham, Matthew T. Seymour, Manuel Salto-Tellez, Helen G. Coleman, Jacqueline James, Graeme I. Murray, Andrew Blake, Stephanie G Craig, Tim Maughan, David Fisher, Darragh G. McArt, Stephen McQuaid
Publikováno v:
British Journal of Cancer
Craig, S G, Humphries, M P, Allerdice, M, Bingham, V, Richman, S D, Loughrey, M B, Coleman, H G, Viratham-Pulsawatdi, A, McCombe, K, Murray, G I, Blake, A, Domingo, E, Domingo, E, Brown, L, Fisher, D, Seymour, M T, Quirke, P, Bankhead, P, McQuaid, S, Lawler, M, McArt, D G, Maughan, T, James, J A & Salto-Tellez, M 2020, ' Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia ', British Journal of Cancer . https://doi.org/10.1038/s41416-020-0985-5
Craig, S G, Humphries, M P, Alderdice, M, Bingham, V, Richman, S D, Loughrey, M B, Coleman, H G, Viratham-Pulsawatdi, A, McCombe, K, Murray, G I, Blake, A, Domingo, E, Robineau, J, Brown, L, Fisher, D, Seymour, M T, Quirke, P, Bankhead, P, McQuaid, S, Lawler, M, McArt, D G, Maughan, T S, James, J A & Salto-Tellez, M 2020, ' Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia ', British Journal of Cancer, vol. 123, no. 8, pp. 1280–1288 . https://doi.org/10.1038/s41416-020-0985-5
Queen's University Belfast-PURE
Craig, S G, Humphries, M P, Allerdice, M, Bingham, V, Richman, S D, Loughrey, M B, Coleman, H G, Viratham-Pulsawatdi, A, McCombe, K, Murray, G I, Blake, A, Domingo, E, Domingo, E, Brown, L, Fisher, D, Seymour, M T, Quirke, P, Bankhead, P, McQuaid, S, Lawler, M, McArt, D G, Maughan, T, James, J A & Salto-Tellez, M 2020, ' Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia ', British Journal of Cancer . https://doi.org/10.1038/s41416-020-0985-5
Craig, S G, Humphries, M P, Alderdice, M, Bingham, V, Richman, S D, Loughrey, M B, Coleman, H G, Viratham-Pulsawatdi, A, McCombe, K, Murray, G I, Blake, A, Domingo, E, Robineau, J, Brown, L, Fisher, D, Seymour, M T, Quirke, P, Bankhead, P, McQuaid, S, Lawler, M, McArt, D G, Maughan, T S, James, J A & Salto-Tellez, M 2020, ' Immune status is prognostic for poor survival in colorectal cancer patients and is associated with tumour hypoxia ', British Journal of Cancer, vol. 123, no. 8, pp. 1280–1288 . https://doi.org/10.1038/s41416-020-0985-5
Queen's University Belfast-PURE
Background Immunohistochemical quantification of the immune response is prognostic for colorectal cancer (CRC). Here, we evaluate the suitability of alternative immune classifiers on prognosis and assess whether they relate to biological features ame
Publikováno v:
British Journal of Cancer
Summary Clinical trials have now identified over 30 cancer histotypes with sensitivity to anti-PD-(L)1 therapies. It is the first time in oncology that a class of drugs has demonstrated such a wide spectrum of activity in monotherapy. This subgroup o
Autor:
Toru Sugiyama, Junzo Kigawa, Hidemichi Watari, Toshiaki Nakamura, Yoshihito Yokoyama, Hiroaki Itamochi, Satoshi Takeuchi, Kimio Ushijima, Daisuke Aoki, Kosuke Yoshihara, Kazuhiro Takehara, Nobuo Yaegashi, Tetsuro Oishi, Yasuhisa Terao, Nao Oumi, Mikio Mikami, Tadashi Kimura
Publikováno v:
British Journal of Cancer
Background: Ovarian clear cell carcinoma (OCCC) is mostly resistant to standard chemotherapy that results in poor patient survival. To understand the genetic background of these tumours, we performed whole-genome sequencing of OCCC tumours. Methods:
Autor:
Meenakshi V. Gupta, Shashi Donthamsetty, Ramneet Kaur, Karuna Mittal, Da Hoon Choi, Michelle D. Reid, Chunhua Yang, Padmashree C.G. Rida, Ritu Aneja
Publikováno v:
British Journal of Cancer
Background: Docetaxel is the only FDA-approved first-line treatment for castration-resistant prostate cancer (CRPC) patients. Docetaxel treatment inevitably leads to tumour recurrence after an initial therapeutic response with generation of multinucl